This profile of MMP gene expression differed from elevated transcription levels of serine-based endopeptidase and proteases, including Prss2, Prss3, Gm5771, and Try4 after treatment with the ACT monotherapy or its combination with OV-CXCR4-A, highlighting dissimilarities in tumor-infiltrating myeloid cell subsets between OV-Fc and OV-CXCR4-A-treatment groups. This evidence concerns the gene PRSS3 and neoplasm.